Abstract

Alzheimer’s disease (AD) is a neurodegenerative disorder and common form of dementia in elderly patients, accounting for 60 to 80 percent of cases worldwide. The hallmark of AD is deposition of neurofibrillary tangles and amyloid plaques in the brain that lead to neurotoxicity and irreversible loss of neurons in the hippocampus and cortex. Based on the onset of age, AD can be classified into early onset (<65 years) and late-onset (≥ 65 years) groups. Genetic factors such as gene mutation as well as environmental factors both can trigger the disease pathogenesis. The preliminary diagnosis can be performed based on the specific clinical symptoms and genetic analysis can help in establishing the familial cases. Treatments are suggested according to the stages of AD, such as mild, moderate, and severe, based on the clinical symptoms and the diagnosis of the patients.This review focuses on overall AD.

• 1.   Zou Z, Liu C, Che C, Huang H. Clinical genetics of Alzheimer’s disease. Biomed Res Int. 2014;2014:291862.
• 2.   Korolev IO. Alzheimer ’s disease : A clinical and basic science review. Medical Student Research Journal. 2014;4(Fall):24–33.
• 3.   Defina PA, Moser RS, Glenn M, Lichtenstein JD, Fellus J. Alzheimer’s disease clinical and research update for health care practitioners. J Aging Res. 2013;2013:207178.
• 4.   Van Giau V, Bagyinszky E, Yang YS, Youn YC, An SSA, Kim SY. Genetic analyses of earlyonset Alzheimer’s disease using next generation sequencing. Sci Rep. 2019;9(1):8368.
• 5.   Giri M, Zhang M, Lü Y. Genes associated with Alzheimer’s disease: An overview and current status. Clin Interv Aging. 2016;11:665–681.
• 6.   Meraz-Ríos MA, Franco-Bocanegra D, Toral Rios D, Campos-Peña V. Early onset Alzheimer’s disease and oxidative stress. Oxid Med Cell Longev. 2014;2014:375968.
• 7.   Rabinovici GD. Late-onset Alzheimer's disease. Continuum (Minneap Minn). 2019;25(1):14–33. 8. Bekris LM, Yu C-E, Bird TD, Tsuang DW. Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol. 2010;23(4):213–227.
• 9.   Cedazo-Mínguez A. Apolipoprotein E and Alzheimer’s disease: Molecular mechanisms and therapeutic opportunities. J Cell Mol Med. 2007;11(6):1227–1238.
• 10.   Kumar A, Singh A, Ekavali. A review on Alzheimer’s disease pathophysiology and its management: An update. Pharmacol Rep. 2015;67(2):195–203.
• 11.   Alzheimer's Association. Alzheimers disease facts and figures. Alzheimers Dement. 2021;17(3):327- 406.
• 12.   DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener. 2019;14(1):32. .
• 13.   Galimberti D, Scarpini E. Treatment of Alzheimer’s disease: Symptomatic and disease-modifying approaches. Curr Aging Sci. 2010;3(1):46–56.
• 14.   Sanabria-Castro A, Alvarado-Echeverría I, MongeBonilla C. Molecular pathogenesis of Alzheimer’s disease: An update. Ann Neurosci. 2017;24(1):46–54.
• 15.   Dai M-H, Zheng H, Zeng L-D, Zhang Y. The genes associated with early-onset Alzheimer’s disease. Oncotarget. 2018;9(19):15132–15143.
• 16.   Chen X-Q, Mobley WC. Alzheimer's disease pathogenesis: Insights from molecular and cellular biology studies of oligomeric Aβ and tau species. Front Neurosci. 2019;13:659.
• 17.   Bi C, Bi S, Li B. Processing of mutant β-amyloid precursor protein and the clinicopathological features of familial Alzheimer’s disease. Aging Dis. 2019;10(2):383. .
• 18.   Tcw J, Goate AM. Genetics of β-amyloid precursor protein in Alzheimer's disease. Cold Spring Harb Perspect Med. 2017;7(6):a024539.
• 19.   Swerdlow RH. Pathogenesis of Alzheimer's disease. Clin Interv Aging. 2007;2(3):347-359.
• 20.   Head E, Phelan M, Doran E, Kim R, Poon W, Schmitt F, Lott I. Cerebrovascular pathology in Down syndrome and Alzheimer's disease. Acta Neuropathol Commun. 2017;5(1):93.
• 21.   Portelius E, Soininen H, Andreasson U, Zetterberg H, Persson R, Karlsson G, Blennow K, Herukka S, Mattsson N. Exploring Alzheimer molecular pathology in Down syndrome cerebrospinal fluid. Neurodegener Dis. 2014;14(2):98-106.
• 22.   Cipriani G, Danti S, Carlesi C, Di Fiorino M. Aging with Down syndrome: The dual diagnosis: Alzheimers disease and Down syndrome. Am J Alzheimers Dis Other Dement. 2018;33(4):253-262.
• 23.   An S, Cai Y, Kim S. Mutations in presenilin 2 and its implications in Alzheimer’s disease and other dementia-associated disorders. Clinical Interv Aging. 2015; 10: 1163.1172.
• 24.   Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med. 2016;18(5):421-430.
• 25.   Dai MH, Zheng H, Zeng LD, Zhang Y. The genes associated with early-onset Alzheimer's disease. Oncotarget. 2017;9(19):15132-15143.
• 26.   Lanoiselée H, Nicolas G, Wallon D, Rovelet-Lecrux A, Lacour M, Rousseau S, et al., APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer's disease: A genetic screening study of familial and sporadic cases. PLoS Med. 2017;14(3):e1002270.
• 27.   Sonntag K, Ryu W, Amirault K, Healy R, Siegel A, McPhie D, Forester B, Cohen B. Late-onset Alzheimer’s disease is associated with inherent changes in bioenergetics profiles. Sci Rep. 2017;7(1): 14038.
• 28.   Kim J, Basak J, Holtzman D. The role of apolipoprotein E in Alzheimer's disease. Neuron. 2009;63(3):287-303.
• 29.   Dong S, Duan Y, Hu Y, Zhao Z. Advances in the pathogenesis of Alzheimer’s disease: A reevaluation of amyloid cascade hypothesis. Trans Neurodegener. 2012;1:18.
• 30.   Lahiri D, Sambamurti K, Bennett D. Apolipoprotein gene and its interaction with the environmentally driven risk factors: Molecular, genetic and epidemiological studies of Alzheimer’s disease. Neurobiol Aging. 2004;25(5):651-660.
• 31.   Olgiati P, Politis A, Papadimitriou G, De Ronchi D, Serretti A. Genetics of late-onset Alzheimer's disease: Update from the Alzgene Database and Analysis of Shared Pathways. Int J Alzheimers Dis 2011;2011:832379.
• 32.   Khanahmadi M, Farhud DD, Malmir M, Orang S. Some biochemical Markers in patients with Alzheimer's disease. Iran J Public Health. 2016;45(10):1355-1358.
• 33.   Holtzman D, Herz J, Bu G. Apolipoprotein E and Apolipoprotein E receptors: Normal biology and roles in Alzheimer's disease. Cold Spring Harb Perspect Med. 2012;2(3):a006312-a006312. 34. Mendez M. Early-onset Alzheimer's disease and its variants. Continuum (Minneap Minn). 2019;25(1):34-51.
• 35.   Isik A. Late onset Alzheimer’s disease in older people. Clini Interv Aging. 2010;5:307-311.
• 36.   Turner RS. Alzheimer's disease. Semin Neurol. 2006;26(5):499-506.
• 37.   Cummings J, Tong G, Ballard C. Treatment combinations for Alzheimer’s disease: Current and future pharmacotherapy options. J Alzheimers Dis. 2019;67(3):779-794.
• 38.   Neugroschl J, Wang S. Alzheimer's disease: diagnosis and treatment across the spectrum of disease severity. Mt Sinai J Med. 2011;78(4):596-612.
• 39.   Bird T. Genetic aspects of Alzheimer's disease. Genet Med. 2008;10(4):231-239.
• 40.   Baldwin S, Farias S. Neuropsychological assessment in the diagnosis of Alzheimer's disease. Curr Proto. Neurosc. 2009; 0.10:10.3.
• 41.   DeFina P, Moser R, Glenn M, Lichtenstein J, Fellus J. Alzheimer's disease clinical and research update for health care practitioners. J Aging Res. 2013;2013: 207178.
• 42.   Schachter A, Davis K. Alzheimer’s disease. Curr Treat Options Neurol. 2000;2(1):51-60.
• 43.   Tellechea P, Pujol N, Esteve-Belloch P, Echeveste B, García-Eulate MR, Arbizu J, Riverol M. Early- and late-onset Alzheimer disease: Are they the same entity? Neurologia. 2018;33(4):244-253.
• 44.   Bondi M, Edmonds E, Salmon D. Alzheimer’s disease: Past, present, and future. J Int Neuropsychol Soc. 2017;23(9-10):818-831.
• 45.   Yiannopoulou KG, Papageorgiou SG. Current and future treatments for Alzheimer's disease. Ther Adv Neurol Disord. 2013;6(1):19-33.
• 46.   Liu P, Xie Y, Meng X, Kang J. History and progress of hypotheses and clinical trials for Alzheimer’s disease. Signal Transduct Target Therapy. 2019;4:29.
• 47.   Weller J, Budson A. Current understanding of Alzheimer's disease diagnosis and treatment. 2018; 7 : F 1000 Faculty Rev-1161.

Data Sharing Statement

Funding